AEON Biopharma (AEON) Projected to Post Quarterly Earnings on Wednesday

Posted by Trevor Kearing on Mar 29th, 2026

AEON Biopharma (NASDAQ:AEON – Get Free Report) will likely be announcing its results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.

AEON Biopharma Price Performance

Shares of AEON opened at $1.17 on Monday. AEON Biopharma has a one year low of $0.38 and a one year high of $1.45. The company has a 50-day simple moving average of $1.12 and a two-hundred day simple moving average of $1.00. The firm has a market capitalization of $13.79 million, a PE ratio of 6.47 and a beta of 0.72.

Institutional Inflows and Outflows

An institutional investor recently raised its position in AEON Biopharma stock. XTX Topco Ltd lifted its position in shares of AEON Biopharma, Inc. (NASDAQ:AEON – Free Report) by 251.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 56,852 shares of the company’s stock after purchasing an additional 40,690 shares during the quarter. XTX Topco Ltd owned about 0.48% of AEON Biopharma worth $63,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 22.78% of the company’s stock.

AEON Biopharma Company Profile

(Get Free Report)

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.